Bank of America Corp /DE/ filed an amended Schedule 13G with the SEC on October 28, 2026, disclosing beneficial ownership of 26,889,300 ordinary shares of Mereo BioPharma Group plc as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Bank of America Corp /DE/ reported aggregate beneficial ownership of 26,889,300 ordinary shares of Mereo BioPharma Group plc.
  • Percentage of class: The filing states the position represents 3.4% of Mereo BioPharma's outstanding ordinary shares.
  • Share base used: The ownership percentage was calculated using 798,454,864 outstanding shares, as disclosed by the issuer in a filing on August 11, 2026, reflecting shares outstanding as of August 10, 2026.
  • Voting and dispositive power: All 26,889,300 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.00.
  • Subsidiaries covered: The filing covers Bank of America Corporation on behalf of itself and wholly owned subsidiaries BofA Securities, Inc. and Merrill Lynch International.
  • Reporting person type: Bank of America Corp /DE/ is classified as a parent holding company (type HC), incorporated in Delaware, with principal offices at 100 N Tryon St, Charlotte, NC 28255.

Bank of America Discloses Amended Ownership Position in Mereo BioPharma

According to the filing, Bank of America Corp /DE/ submitted Amendment No. 1 to its Schedule 13G to report its beneficial ownership in Mereo BioPharma Group plc, a biopharmaceutical company headquartered at One Cavendish Place, Fourth Floor, London, United Kingdom, W1G 0QF. The event triggering the amendment occurred on September 30, 2026, and the statement was signed by Monica Yako, Authorized Signatory, on October 28, 2026. The securities covered are ordinary shares with CUSIP number G6014T100, identified in the filing using the CINS designation for the issuer's common stock.

The filing discloses that the 26,889,300 shares are held entirely through shared power arrangements, with no shares held under sole voting or sole dispositive authority. Bank of America Corporation filed the statement on behalf of two wholly owned subsidiaries: BofA Securities, Inc., described as "a broker dealer registered under section 15 of the Act (15 U.S.C. 78o)," and Merrill Lynch International, identified as "a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J)." Item 5 of the filing confirms the position represents ownership of 5 percent or less of the class.

The filing further certifies, in the words of the standard Schedule 13G certification, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Item 6 states that ownership of more than 5 percent on behalf of another person is "Not Applicable," and Items 8 and 9, covering group membership and dissolution of a group, are likewise noted as "Not Applicable."

What Was Disclosed

Bank of America Corp /DE/ filed an amended Schedule 13G reporting 26,889,300 ordinary shares of Mereo BioPharma Group plc, equaling 3.4% of the class, with all shares held under shared voting and dispositive power as of September 30, 2026.